Celgene Scientist II, Preclinical Sciences - In vivo pharmacology in Cambridge, Massachusetts

Description

Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of human health. We value our passion for patients, ​quest for innovation, spirit of independence and love of challenge. With a presence in more than 70 countries, and growing - we look for talented people to grow our business, advance our science and contribute to our unique culture.

Summary/ScopeThe Scientist II, Preclinical Sciences will provide scientific support to the discovery organization by providing knowledge and experience in in vivo proof of principle support for small molecule target validation, specifically in the immunology/inflammation disease area. Experience in flow cytometry, as a component of the ex vivo analysis of rodent samples, is highly desired. The pharmacologist/immunologist will participate at the discovery project team level, and will assure a quality product delivery for team decision making. This role includes both a bench presence and project team membership, and will require that the candidate can navigate both of these responsibilities.Responsibilities will include, but are not limited to, the following:1. Knowledge of and direct experience with models of inflammatory disease (IBD, psoriasis, arthritis/spondylitis) and endpoints/drives of disease in rodent models.3. Experience in flow cytometry of samples collected from pharmacology studies, including analysis and interpretation for discovery teams.4. Active participation as a member of discovery teams to provide knowledge from the pharmacology discipline.

Skills/Knowledge Required:• PhD in Pharmacology, Immunology or Cell Biology with at least 4 years relevant pharmaceutical R&D experience preferred.• Solid understand of in vivo models of inflammatory disease, including ex vivo evaluations of small molecules targeted to immune/inflammatory disease targets.• Ability to communicate to a broader discovery team and make recommendations from the preclinical pharmacology perspective• Experience in flow cytometry execution and interpretation• Ability to generate protocols, and record data in a notebook (electronic or hardcopy)Skills/Knowledge Desired:• Knowledge of immunology/inflammation• Knowledge of in vitro assessment of pharmacologic activityPersonal characteristics• Strong presence as well as sense of urgency and priorities as well as flexibility. The ability and strong desire to "make things happen".• High level of honesty and integrity.• Excellent interpersonal skills with particular emphasis on communication & relationship building.• Motivated to be part of an organization that aims to make a difference through cutting edge research.• Passion for the pharmaceutical industry.

#LI-POST

Celgene is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Celgene complies with all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act. All applicants must have authorization to work for Celgene in the U.S.COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE

At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”

There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.